Clinical Application RR Example - Revision history

MriFranz: /* Example Registered Report Abstract - Clinical Application */ new format

2025-07-04T15:20:09Z

Example Registered Report Abstract - Clinical Application: new format

← Older revision		Revision as of 17:20, 4 July 2025
Line 5:		Line 5:

	== Introduction ==		== Introduction ==
			=== Background and motivation ===
	Major Depressive Disorder (MDD) affects approximately 7% of the adult population and remains difficult to diagnose objectively. Previous studies suggest neurochemical abnormalities in MDD patients that could be detected through Magnetic Resonance Spectroscopy (MRS). However, findings have been inconsistent due to methodological variations and small sample sizes. This registered report outlines a confirmatory study designed to identify reliable metabolic biomarkers in the anterior cingulate cortex (ACC) that distinguish MDD patients from healthy controls.		Major Depressive Disorder (MDD) affects approximately 7% of the adult population and remains difficult to diagnose objectively. Previous studies suggest neurochemical abnormalities in MDD patients that could be detected through Magnetic Resonance Spectroscopy (MRS). However, findings have been inconsistent due to methodological variations and small sample sizes. This registered report outlines a confirmatory study designed to identify reliable metabolic biomarkers in the anterior cingulate cortex (ACC) that distinguish MDD patients from healthy controls.

	== Hypothesis ==		=== Hypothesis ===
	We hypothesize that MDD patients will show significantly reduced GABA/Cr ratios and elevated Glu/Cr ratios in the ACC compared to matched healthy controls, with effect sizes of d≥0.75 for GABA/Cr and d≥0.65 for Glu/Cr.		We hypothesize that MDD patients will show significantly reduced GABA/Cr ratios and elevated Glu/Cr ratios in the ACC compared to matched healthy controls, with effect sizes of d≥0.75 for GABA/Cr and d≥0.65 for Glu/Cr.

	== ~~Preliminary Data~~ ==		== Methodology ==
	~~We present two complementary approaches to justify our effect size estimates:~~

	~~'''Option 1: Exploratory Study Results''' In our pilot study~~ (n=12 MDD patients, n=12 controls)~~, we measured six metabolites (NAA, Cho, Cr, mI, GABA, Glu) in~~ the ACC using MEGA-PRESS at 3T. GABA/Cr ratios showed the largest difference (21.7% reduction in MDD vs. controls, p=0.022, d=0.82), followed by Glu/Cr ratios (16.3% increase in MDD, p=0.048, d=0.67). Other metabolites showed smaller, non-significant differences (p>0.05).		We performed a systematic review of 15 MRS studies in MDD (cumulative n=423 MDD patients, n=379 controls) by querying PubMed with the keywords "Major Depressive Disorder"+"MR Spectroscopy".

	~~'''Option 2: Literature-Based Effect Size''' Our~~ systematic review ~~of 15 MRS studies in MDD (cumulative n=423 MDD patients, n=379 controls)~~ revealed consistent GABA deficits in the ACC with pooled effect sizes ranging from d=0.65-0.89. Meta-regression showed larger effects in medication-naïve patients (d=0.78, 95% CI [0.63-0.93]). Glutamate findings were more heterogeneous but suggested moderate elevations (d=0.62, 95% CI [0.46-0.78]) in ACC.		== Current status and Preliminary Results ==
			The systematic review revealed consistent GABA deficits in the ACC with pooled effect sizes ranging from d=0.65-0.89. Meta-regression showed larger effects in medication-naïve patients (d=0.78, 95% CI [0.63-0.93]). Glutamate findings were more heterogeneous but suggested moderate elevations (d=0.62, 95% CI [0.46-0.78]) in ACC.

	== ~~Study Protocol~~ ==		== Plan and Outlook ==
			=== Study Protocol ===
	=== Study ~~Design and Population~~ ===
	This confirmatory cross-sectional study will include 42 medication-naïve MDD patients (diagnosed using DSM-5 criteria, HAMD-17 score ≥18) and 42 age- and sex-matched healthy controls. Exclusion criteria include other psychiatric disorders, neurological disease, substance use disorder, and MRI contraindications.		This confirmatory cross-sectional study will include 42 medication-naïve MDD patients (diagnosed using DSM-5 criteria, HAMD-17 score ≥18) and 42 age- and sex-matched healthy controls. Exclusion criteria include other psychiatric disorders, neurological disease, substance use disorder, and MRI contraindications.

	~~=== MR Acquisition Protocol ===~~
	All participants will undergo 3T MRS (Siemens MAGNETOM Prisma) with:		All participants will undergo 3T MRS (Siemens MAGNETOM Prisma) with:

Line 30:		Line 29:
	* Additional T1-weighted imaging for tissue composition correction		* Additional T1-weighted imaging for tissue composition correction

	~~=== Clinical Assessments ===~~
	All participants will complete:		All participants will complete:

Line 38:		Line 36:
	* Demographic and medical history questionnaires		* Demographic and medical history questionnaires

	== Statistical Analysis Plan ==		=== Statistical Analysis Plan ===

	=== Primary Outcomes ===		==== Primary Outcomes ====

	# GABA/Cr ratio differences between MDD and control groups		# GABA/Cr ratio differences between MDD and control groups
	# Glu/Cr ratio differences between MDD and control groups		# Glu/Cr ratio differences between MDD and control groups

	=== Secondary Outcomes ===		==== Secondary Outcomes ====

	# Correlation between GABA/Cr and depression severity		# Correlation between GABA/Cr and depression severity
Line 51:		Line 49:
	# Exploratory analysis of other metabolites (NAA, Cho, mI)		# Exploratory analysis of other metabolites (NAA, Cho, mI)

	=== Sample Size Justification ===		==== Sample Size Justification ====
	Based on our ~~pilot data and~~ literature review, we estimate effect sizes of d=0.75 for GABA/Cr and d=0.65 for Glu/Cr. Power analysis indicates that 42 subjects per group will provide 90% power to detect both effects at α=0.025 (Bonferroni-corrected for two primary outcomes).		Based on our literature review, we estimate effect sizes of d=0.75 for GABA/Cr and d=0.65 for Glu/Cr. Power analysis indicates that 42 subjects per group will provide 90% power to detect both effects at α=0.025 (Bonferroni-corrected for two primary outcomes).

	=== Statistical Methods ===		==== Statistical Methods ====

	* Independent samples t-tests for between-group comparisons (with Bonferroni correction)		* Independent samples t-tests for between-group comparisons (with Bonferroni correction)

MriFranz: /* Title: Magnetic Resonance Spectroscopy for Detecting Metabolic Alterations in Major Depressive Disorder: A Registered Report */

2025-05-27T12:30:35Z

Title: Magnetic Resonance Spectroscopy for Detecting Metabolic Alterations in Major Depressive Disorder: A Registered Report

← Older revision		Revision as of 14:30, 27 May 2025
Line 1:		Line 1:
	= Example Registered Report Abstract - Clinical Application =		= Example Registered Report Abstract - Clinical Application =

	== Title: Magnetic Resonance Spectroscopy for Detecting Metabolic Alterations in Major Depressive Disorder: A Registered Report ==		== Title ==
			'''Magnetic Resonance Spectroscopy for Detecting Metabolic Alterations in Major Depressive Disorder: A Registered Report'''

	== Introduction ==		== Introduction ==

MriFranz: Text

2025-05-27T08:51:55Z

Text

← Older revision		Revision as of 10:51, 27 May 2025
Line 1:		Line 1:
	= Example Registered Report Abstract - Clinical Application =		= Example Registered Report Abstract - Clinical Application =

			== Title: Magnetic Resonance Spectroscopy for Detecting Metabolic Alterations in Major Depressive Disorder: A Registered Report ==

			== Introduction ==
			Major Depressive Disorder (MDD) affects approximately 7% of the adult population and remains difficult to diagnose objectively. Previous studies suggest neurochemical abnormalities in MDD patients that could be detected through Magnetic Resonance Spectroscopy (MRS). However, findings have been inconsistent due to methodological variations and small sample sizes. This registered report outlines a confirmatory study designed to identify reliable metabolic biomarkers in the anterior cingulate cortex (ACC) that distinguish MDD patients from healthy controls.

			== Hypothesis ==
			We hypothesize that MDD patients will show significantly reduced GABA/Cr ratios and elevated Glu/Cr ratios in the ACC compared to matched healthy controls, with effect sizes of d≥0.75 for GABA/Cr and d≥0.65 for Glu/Cr.

			== Preliminary Data ==
			We present two complementary approaches to justify our effect size estimates:

			'''Option 1: Exploratory Study Results''' In our pilot study (n=12 MDD patients, n=12 controls), we measured six metabolites (NAA, Cho, Cr, mI, GABA, Glu) in the ACC using MEGA-PRESS at 3T. GABA/Cr ratios showed the largest difference (21.7% reduction in MDD vs. controls, p=0.022, d=0.82), followed by Glu/Cr ratios (16.3% increase in MDD, p=0.048, d=0.67). Other metabolites showed smaller, non-significant differences (p>0.05).

			'''Option 2: Literature-Based Effect Size''' Our systematic review of 15 MRS studies in MDD (cumulative n=423 MDD patients, n=379 controls) revealed consistent GABA deficits in the ACC with pooled effect sizes ranging from d=0.65-0.89. Meta-regression showed larger effects in medication-naïve patients (d=0.78, 95% CI [0.63-0.93]). Glutamate findings were more heterogeneous but suggested moderate elevations (d=0.62, 95% CI [0.46-0.78]) in ACC.

			== Study Protocol ==

			=== Study Design and Population ===
			This confirmatory cross-sectional study will include 42 medication-naïve MDD patients (diagnosed using DSM-5 criteria, HAMD-17 score ≥18) and 42 age- and sex-matched healthy controls. Exclusion criteria include other psychiatric disorders, neurological disease, substance use disorder, and MRI contraindications.

			=== MR Acquisition Protocol ===
			All participants will undergo 3T MRS (Siemens MAGNETOM Prisma) with:

			* MEGA-PRESS sequence for GABA (TE=68ms, TR=2000ms, 256 averages)
			* PRESS sequence for other metabolites (TE=30ms, TR=2000ms, 128 averages)
			* Voxel placement: 2×2×2cm³ in the dorsal ACC
			* Additional T1-weighted imaging for tissue composition correction

			=== Clinical Assessments ===
			All participants will complete:

			* HAMD-17 and BDI-II for depression severity
			* STAI for anxiety symptoms
			* Structured clinical interview (SCID-5)
			* Demographic and medical history questionnaires

			== Statistical Analysis Plan ==

			=== Primary Outcomes ===

			# GABA/Cr ratio differences between MDD and control groups
			# Glu/Cr ratio differences between MDD and control groups

			=== Secondary Outcomes ===

			# Correlation between GABA/Cr and depression severity
			# Correlation between Glu/Cr and depression severity
			# Exploratory analysis of other metabolites (NAA, Cho, mI)

			=== Sample Size Justification ===
			Based on our pilot data and literature review, we estimate effect sizes of d=0.75 for GABA/Cr and d=0.65 for Glu/Cr. Power analysis indicates that 42 subjects per group will provide 90% power to detect both effects at α=0.025 (Bonferroni-corrected for two primary outcomes).

			=== Statistical Methods ===

			* Independent samples t-tests for between-group comparisons (with Bonferroni correction)
			* ANCOVA with age, sex, and gray matter fraction as covariates
			* Pearson correlations for metabolite-symptom associations
			* ROC analysis to determine diagnostic utility

MriFranz: example

2025-05-27T08:50:53Z

example

New page

= Example Registered Report Abstract - Clinical Application =